Seizure freedom · patients with drug‐resistant epilepsy
PUFA may leads to higher seizure freedom compared with placebo (low certainty).
1 finding from 1 review
50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐ Older (19 years or more) · patients with drug‐resistant epilepsy
PUFA showed no clear difference in 50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐… compared with placebo (low certainty).
1 finding from 1 review
50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐ Younger (< 19 years) · patients with drug‐resistant epilepsy
PUFA may leads to higher 50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐… compared with placebo (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · patients with drug‐resistant epilepsy
PUFA showed no clear difference in 50% reduction in seizures frequency (6 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Potential adverse effects ‐ not reported · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal effects · patients with drug‐resistant epilepsy
PUFA showed no clear difference in gastrointestinal effects compared with placebo (low certainty).
1 finding from 1 review
Depressive symptomology (continuous) HDRS where possible; higher scores indicate greater symptomology · adults with Major Depressive Disorder
1 finding from 1 review
Adverse events Study reports · adults with Major Depressive Disorder
It is very uncertain whether n3PUFAs changes adverse eventsStudy reports compared with placebo (very low certainty).
1 finding from 1 review
Depressive symptomology (dichotomous ‐ remission) Depressive symptomology rating scale as used by authors · adults with Major Depressive Disorder
n3PUFAs showed no clear difference in depressive symptomology (dichotomous ‐ remission)Depressive… compared with placebo (low certainty).
1 finding from 1 review
Depressive symptomology (dichotomous ‐ response) Depressive symptomology rating scale as used by authors · adults with Major Depressive Disorder
n3PUFAs showed no clear difference in depressive symptomology (dichotomous ‐ response)Depressive… compared with placebo (low certainty).
1 finding from 1 review
Quality of lifeValidated quality of life scales as used by authors, CGI (7‐point scale) where possible, higher scores indicate poorer quality of life · adults with Major Depressive Disorder
1 finding from 1 review
Trial non‐completionStudy reports · adults with Major Depressive Disorder
It is very uncertain whether n3PUFAs changes trial non‐completionStudy reports compared with placebo (very low certainty).
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with oral omega‐6 PUFAs (moderate certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in ocular surface staining at 1‐month compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs may leads to higher adverse event: gastrointestinal disorders at 1‐month (with actual compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
All‐cause mortality · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
1 finding from 1 review
Adiposity · people with or without existing cardiovascular disease, men and women
1 finding from 1 review